Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant anlotinib after radical surgery for stage IA non-small cell lung cancer
ChiCTR1800019607Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 5-year disease-free survival. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019607.